Sanara MedTech Inc.
No enriched coverage for $SMTI in the last 7 days.
No SEC Form 4 filings for $SMTI in the last 30 days.
MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...
Sanara MedTech, a Fort Worth surgical tissue repair products maker, is being acquired by MiMedx Group for cash and stock valued at $350M, according to the deal announcement. MiMedx expects the combined business to have over $400M in annual revenue and to accelerate double-digit growth. The transaction is expected to close by year-end.
Recent SMTI coverage spans mergers & acquisitions, financial news and corporate actions.
MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
SMTI should trade primarily on deal premium, exchange ratio, and closing probability, with potential spread compression as approvals progress.
Sanara MedTech, a Fort Worth surgical tissue repair products maker, is being acquired by MiMedx Group for cash and stock valued at $350M, according to the deal announcement. MiMedx expects the combined business to have over $400M in annual revenue and to accelerate double-digit growth. The transaction is expected to close by year-end.
MiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.
Definitive M&A terms create a clear catalyst for spread trading and takeover premium expectations.
alphai scores every news story that mentions SMTI with an AI model for sentiment and relevance, and aggregates insider trades from Sanara MedTech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
4 min readTransformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...
4 min readSanara MedTech, a Fort Worth surgical tissue repair products maker, is being acquired by MiMedx Group for cash and stock valued at $350M, according to the deal announcement. MiMedx expects the combined business to have over $400M in annual revenue and to accelerate double-digit growth. The transaction is expected to close by year-end.
2 min readMiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.
4 min readBiotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
3 min readSanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of July 29, 2026 among SANARA MEDTECH INC., MIMEDX GROUP, INC. and MUSTANG MERGER SUB, INC. TABLE OF CONTENTS Article 1 Definitions Section 1.1 Definitions 2 Section 1.2 Other Definition
2 min readSanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000714256 0000714256 2026-06-04 2026-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readSanara MedTech Inc. (SMTI) reported record full-year 2025 net revenue of $103.1 million, a 19% increase year-over-year, and expanded its gross margin to 93%. The company significantly reduced its net loss and improved adjusted EBITDA, generating substantial cash from operations. Strategic growth was driven by an expanded distributor network and a significant Vizient contract, positioning SMTI for continued growth in 2026.
3 min readSanara MedTech Inc. announced strong financial results for the full year 2025, with net revenue exceeding $100 million for the first time, marking a 19% increase year-over-year. The company also reported a 5% increase in fourth-quarter net revenue and reaffirmed its financial guidance for full-year 2026, anticipating 13% to 17% growth. Key operational achievements include an Innovative Technology contract for its BIASURGE product and the publication of a peer-reviewed study on its CellerateRX Surgical Powder.
3 min readATLANTA, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. ( "Sanara" or "the Company" ) ( NASDAQ:SMTI ) complied with federal securities laws.
2 min read
